Mechanisms of biliary carcinogenesis and growth

World Journal of Gastroenterology

Volumn 14, Issue 19, 2008, Pages 2986-2989

  Wise, Candace ^a   Pilanthananond, Metaneeya ^a   Perry, Benjamin F ^b   Alpini, Gianfranco ^a,c   McNeal, Michael ^b   Glaser, Shannon S ^a  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b TEXAS A AND M UNIVERSITY SYSTEM   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Biliary carcinogenesis; Cholangiocarcinomas; Primary biliary cirrhosis; Primary sclerosing cholangitis

Indexed keywords

4 AMINOBUTYRIC ACID; ANANDAMIDE; APC PROTEIN; B RAF KINASE; CYCLOOXYGENASE 2 INHIBITOR; ENDOCANNABINOID; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; INTERLEUKIN 8; K RAS PROTEIN; MUSCARINIC RECEPTOR; PLATELET DERIVED GROWTH FACTOR; PROTEIN MCL 1; PROTEIN P16; PROTEIN P53; SCATTER FACTOR; SMAD4 PROTEIN; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; VASCULOTROPIN;

APOPTOSIS; BILE DUCT CARCINOMA; BILIARY CARCINOGENESIS; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; CHOLECYSTITIS; CHROMOSOME DELETION; DISEASE ASSOCIATION; DNA DAMAGE; GALLSTONE; GENE OVEREXPRESSION; HUMAN; MALIGNANT TRANSFORMATION; MOLECULAR DYNAMICS; MUTATION; NONALCOHOLIC FATTY LIVER; OBESITY; ONCOGENE; PRIMARY SCLEROSING CHOLANGITIS; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; RISK FACTOR; SMOKING; TUMOR CELL; ULCERATIVE COLITIS; VIRUS INFECTION;

EID: 48049122864     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.2986     Document Type: Review

References (39)

1. Alpini G, Prall RT, LaRusso NF. The pathobiology of biliary epithelia. The Liver; Biology & Pathobiology, 4E I M Arias, Boyer JL, Chisari FV, Fausto N, Jakoby W, Schachter D, and Shafritz D. Philadelphia: Lippincott Williams & Wilkins, 2001: 421-435
2. Roberts SK, Ludwig J, Larusso NF. The pathobiology of biliary epithelia. Gastroenterology 1997; 112: 269-279
3. Ahrendt SA, Nakeeb A, Pitt HA. Cholangiocarcinoma. Clin Liver Dis 2001; 5: 191-218
4. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002; 2: 10
5. Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 33-42
6. Annual Report of the US Organ Procurement. Transplantation Network and the Scientific Registry for Transplant Recipients: Transplant Data 1991-2000
7. Alvaro D, Mancino MG, Glaser S, Gaudio E, Marzioni M, Francis H, Alpini G. Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. Gastroenterology 2007; 132: 415-431
8. Malhi H, Gores GJ. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol 2006; 45: 856-867
9. Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology 2005; 128: 1655-1667
10. Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, Khan SA, Elliott P, Thomas HC. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 2001; 48: 816-820
11. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002; 37: 806-813
12. Davila JA, El-Serag HB. Cholangiocarcinoma: the "other" liver cancer on the rise. Am J Gastroenterol 2002; 97: 3199-200
13. Gores GJ. Cholangiocarcinoma: current concepts and insights. Hepatology 2003; 37: 961-969
14. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Thursz MR, Wasan H. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002; 51 Suppl 6: VI1-VI9
15. Welzel TM, Graubard BI, El-Serag HB, Shaib YH, Hsing AW, Davila JA, McGlynn KA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 2007; 5: 1221-1228
16. Okuda K, Nakanuma Y, Miyazaki M. Cholangiocarcinoma: recent progress. Part 2: molecular pathology and treatment. J Gastroenterol Hepatol 2002; 17: 1056-1063
17. Okuda K, Nakanuma Y, Miyazaki M. Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology. J Gastroenterol Hepatol 2002; 17: 1049-1055
18. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 2000; 60: 184-190
19. Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin 2006; 56: 69-83
20. Berthiaume EP, Wands J. The molecular pathogenesis of cholangiocarcinoma. Semin Liver Dis 2004; 24: 127-137
21. Jaiswal M, LaRusso NF, Shapiro RA, Billiar TR, Gores GJ. Nitric oxide-mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes. Gastroenterology 2001; 120: 190-199
22. Endo K, Yoon BI, Pairojkul C, Demetris AJ, Sirica AE. ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology 2002; 36: 439-450
23. Lai GH, Zhang Z, Shen XN, Ward DJ, Dewitt JL, Holt SE, Rozich RA, Hixson DC, Sirica AE. erbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer. Gastroenterology 2005; 129: 2047-2057
24. Taniai M, Higuchi H, Burgart LJ, Gores GJ. p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology 2002; 123: 1090-1098
25. Rashid A. Cellular and molecular biology of biliary tract cancers. Surg Oncol Clin N Am 2002; 11: 995-1009
26. Ishimura N, Bronk SF, Gores GJ. Inducible nitric oxide synthase upregulates cyclooxygenase-2 in mouse cholangiocytes promoting cell growth. Am J Physiol Gastrointest Liver Physiol 2004; 287: G88-G95
27. Ishimura N, Bronk SF, Gores GJ. Inducible nitric oxide synthase up-regulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis. Gastroenterology 2005; 128: 1354-1368
28. Park J, Tadlock L, Gores GJ, Patel T. Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology 1999; 30: 1128-1133
29. Isomoto H, Kobayashi S, Werneburg NW, Bronk SF, Guicciardi ME, Frank DA, Gores GJ. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 2005, 42: 1329-1338
30. Kobayashi S, Werneburg NW, Bronk SF, Kaufmann SH, Gores GJ. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology 2005; 128: 2054-2065
31. Mott JL, Kobayashi S, Bronk SF, Gores GJ. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007; 26: 6133-6140
32. Marzioni M, Fava G, Benedetti A. Nervous and Neuroendocrine regulation of the pathophysiology of cholestasis and of biliary carcinogenesis. World J Gastroenterol 2006; 12: 3471-3480
33. Kanno N, Lesage G, Phinizy JL, Glaser S, Francis H, Alpini G. Stimulation of alpha2-adrenergic receptor inhibits cholangiocarcinoma growth through modulation of Raf-1 and B-Raf activities. Hepatology 2002; 35: 1329-1340
34. Alvaro D, Alpini G, Jezequel AM, Bassotti C, Francia C, Fraioli F, Romeo R, Marucci L, Le Sage G, Glaser SS, Benedetti A. Role and mechanisms of action of acetylcholine in the regulation of rat cholangiocyte secretory functions. J Clin Invest 1997; 100: 1349-1362
35. LeSagE G, Alvaro D, Benedetti A, Glaser S, Marucci L, Baiocchi L, Eisel W, Caligiuri A, Phinizy JL, Rodgers R, Francis H, Alpini G. Cholinergic system modulates growth, apoptosis, and secretion of cholangiocytes from bile duct-ligated rats. Gastroenterology 1999; 117: 191-199
36. Fava G, Marucci L, Glaser S, Francis H, De Morrow S, Benedetti A, Alvaro D, Venter J, Meininger C, Patel T, Taffetani S, Marzioni M, Summers R, Reichenbach R, Alpini G. gamma-Aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway. Cancer Res 2005; 65: 11437-11446
37. Sampson LK, Vickers SM, Ying W, Phillips JO. Tamoxifen-mediated growth inhibition of human cholangiocarcinoma. Cancer Res 1997; 57: 1743-1749
38. Alvaro D, Barbaro B, Franchitto A, Onori P, Glaser SS, Alpini G, Francis H, Marucci L, Sterpetti P, Ginanni-Corradini S, Onetti Muda A, Dostal DE, De Santis A, Attili AF, Benedetti A, Gaudio E. Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol 2006; 169: 877-888
39. DeMorrow S, Glaser S, Francis H, Venter J, Vaculin B, Vaculin S, Alpini G. Opposing actions of endocannabinoids on cholangiocarcinoma growth: recruitment of Fas and Fas ligand to lipid rafts. J Biol Chem 2007; 282: 13098-13113